课题基金 / 基金详情

Divergent Functions of ERK Substrate Binding Domains in Pathogenesis of Myeloproliferative Neoplasms

Divergent Functions of ERK Substrate Binding Domains in Pathogenesis of Myeloproliferative Neoplasms
ERK 底物结合域在骨髓增生性肿瘤发病机制中的不同功能
批准号:
10719088
负责人:
TOMASZ SKORSKI
金额:
$70.7万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-07-06 至 2028-06-30

项目摘要

项目成果

TOMASZ SKORSKI的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结/文摘
英文摘要
PROJECT SUMMARY/ABSTRACT The Ras/MAPK pathway is activated in 85% of human cancer. Nevertheless, attempts to target Ras/MAPK signaling have produced only limited efficacy. We hypothesize that one reason for the failure to successfully target this pathway is that the targeting efforts have focused on the active sites of kinases in this cascade, which has failed to provide long-lasting benefit. We hypothesize that the failure of this approach results from two causes: 1) Active site inhibitors, which resemble adenosine triphosphate (ATP), must overcome the exceedingly high cytosolic ATP levels in cancer cells; and 2) critical kinases in this cascade (e.g., ERK1/2) have distinct substrate interactions domains that can perform antagonistic roles in regulating cancer progression. Consequently, active-site focused inhibition is akin to simultaneous depression of the accelerator and brake pedals of an automobile. We hypothesize that a more successful approach will be to develop inhibitors which preserve kinase activity, but divert it exclusively to “brake pedal” substrates. In support, we have demonstrated that the two substrate binding domains of ERK2, termed the D and DPB domains, play opposing roles in the pathogenesis of JAK2-kinase driven myeloproliferative neoplasms (MPN). Indeed, the DBP and D domains act like brake and accelerator pedals, opposing and promoting disease progression, respectively. Consequently, pharmacologic attenuation of the accelerator pedal (D-domain) or its substrates should impair tumor progression more potently than active site inhibition, because it selectively interferes with the disease promoting activity of ERK2, while preserving the tumor suppressive function of the DBP-domain. While we have compelling evidence for the opposing roles of the ERK2-D and DBP domains, the molecular basis for their action remains unclear and this is an impediment to developing effective, pharmacologic interventions focused on the ERK2 D domain. We now seek to address this gap in knowledge according to the following aims. We will: 1) Assess the generality of the opposing functions of the ERK2-D and DBP domains in the pathogenesis of distinct MPN subtypes; 2) Understand the mechanistic basis by which the ERK2-D and DBP domains exert their distinct functions; and 3) Assess the efficacy of pharmacologic targeting of the ERK2-D domain and/or its targets in inhibiting cancer progression. Through these efforts we expect to bring new insights into the role of ERK2 substrate binding modules in regulating cancer progression and how to exploit this information therapeutically. While we begin with MPN, these findings may have far reaching implications for other Ras/MAPK driven cancers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Oncogenic tyrosine kinases inhibitors abrogate DNA repair and sensitive leukemias to PARP inhibitors
  • 批准号:
    10374000
  • 项目类别:
  • 资助金额:
    $39.96万
  • 财政年份:
    2020
  • 负责人:
    TOMASZ SKORSKI
  • 依托单位:
MPN-inducing mutations as biomarkers of synthetic lethality
  • 批准号:
    10444919
  • 项目类别:
  • 资助金额:
    $41.98万
  • 财政年份:
    2020
  • 负责人:
    TOMASZ SKORSKI
  • 依托单位:
MPN-inducing mutations as biomarkers of synthetic lethality
  • 批准号:
    10652426
  • 项目类别:
  • 资助金额:
    $41.98万
  • 财政年份:
    2020
  • 负责人:
    TOMASZ SKORSKI
  • 依托单位:
Oncogenic tyrosine kinases inhibitors abrogate DNA repair and sensitive leukemias to PARP inhibitors
  • 批准号:
    10608045
  • 项目类别:
  • 资助金额:
    $39.96万
  • 财政年份:
    2020
  • 负责人:
    TOMASZ SKORSKI
  • 依托单位:
海外基金